Amoeba SA Cash Flow Conversion Efficiency
Amoeba SA cash flow conversion efficiency. Based on the latest financial reports, Amoeba SA (ALMIB) has a cash flow conversion efficiency ratio of 0.644x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.45 Million ≈ $-4.04 Million USD) by net assets (€-5.36 Million ≈ $-6.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Amoeba SA (2012–2025)
Cash flow conversion efficiency of Amoeba SA from 2012 to 2025. This chart illustrates how Amoeba SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Amoeba SA (ALMIB) share price today for real-time trading data and today's change.
Amoeba SA Cash Flow Conversion Ratio Explained
Amoeba SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Amoeba SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amoeba SA ranked by their cash flow conversion efficiency. Also see ALMIB market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Minho M Bhd
KLSE:5576
|
0.014x |
|
LS telcom AG
XETRA:LSX
|
0.485x |
|
Aspermont Ltd
AU:ASP
|
0.082x |
|
Eclipse Metals Ltd
AU:EPM
|
-0.064x |
|
DarioHealth Corp
NASDAQ:DRIO
|
-0.100x |
|
Agtira AB
ST:AGTIRA-B
|
N/A |
|
Panorama Sentrawisata Tbk
JK:PANR
|
0.015x |
|
Eagon Holdings Co.Ltd
KQ:039020
|
0.005x |
Annual Cash Flow Conversion Efficiency for Amoeba SA (2012–2025)
The table below shows the annual cash flow conversion efficiency of Amoeba SA from 2012 to 2025. Review ALMIB cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-5.36 Million ≈ $-6.27 Million |
€-6.13 Million ≈ $-7.16 Million |
1.143x | +182.19% |
| 2024-12-31 | €-10.41 Million ≈ $-12.17 Million |
€-4.22 Million ≈ $-4.93 Million |
0.405x | -75.44% |
| 2023-12-31 | €-3.94 Million ≈ $-4.61 Million |
€-6.50 Million ≈ $-7.60 Million |
1.649x | +349.19% |
| 2022-12-31 | €8.16 Million ≈ $9.54 Million |
€-5.40 Million ≈ $-6.32 Million |
-0.662x | +97.77% |
| 2021-12-31 | €198.68K ≈ $232.28K |
€-5.90 Million ≈ $-6.90 Million |
-29.704x | -1727.93% |
| 2020-12-31 | €2.00 Million ≈ $2.34 Million |
€-3.25 Million ≈ $-3.80 Million |
-1.625x | -89.00% |
| 2019-12-31 | €4.23 Million ≈ $4.94 Million |
€-3.64 Million ≈ $-4.25 Million |
-0.860x | +12.73% |
| 2018-12-31 | €5.41K ≈ $6.33K |
€-5.33K ≈ $-6.23K |
-0.985x | -142.87% |
| 2017-12-31 | €12.52K ≈ $14.64K |
€-5.08K ≈ $-5.94K |
-0.406x | -32.43% |
| 2016-12-31 | €18.63K ≈ $21.78K |
€-5.71K ≈ $-6.67K |
-0.306x | +22.04% |
| 2015-12-31 | €10.60K ≈ $12.39K |
€-4.16K ≈ $-4.87K |
-0.393x | +7.81% |
| 2014-12-31 | €2.80 Million ≈ $3.27 Million |
€-1.19 Million ≈ $-1.39 Million |
-0.426x | -136.98% |
| 2013-12-31 | €433.99K ≈ $507.38K |
€500.21K ≈ $584.79K |
1.153x | +771.59% |
| 2012-12-31 | €947.20K ≈ $1.11 Million |
€-162.56K ≈ $-190.04K |
-0.172x | -- |
About Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more